UK single centre experience of rare and atypical variant of castrate-resistant prostate cancer: Poorly differentiated neuroendocrine small-cell carcinoma
Journal of Clinical Urology, Volume 8, Pages 19-29
Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS)
European Urology, Volume 67, Issue 4, April 2015, Pages 673-679
Relationships Between Times to Testosterone and Prostate-Specific Antigen Rises During the First Off-Treatment Interval of Intermittent Androgen Deprivation are Prognostic for Castration Resistance in Men With Nonmetastatic Prostate Cancer
Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials
Ann Oncol., Volume 26, Issue 4, April 2015, Pages 743-749